



IBA Provides Update on its Global Proton Therapy Business at Capital Markets Day Today

- IBA selected for second gantry treatment room at the Krakow Proton Therapy Centre worth EUR 15 million to IBA
- Full Repayment of EUR 31.5 million loan for Trento Proton Therapy Center Received

Louvain-la-Neuve, Belgium, October 9, 2013 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, is hosting a Capital Markets Day today for analysts and investors in London, UK. IBA also announces today that the company has been selected to supply the proton therapy equipment for the new extension to the Krakow Proton Therapy Centre, Poland, in a contract worth EUR 15 million to IBA. Furthermore IBA is pleased to announce that it has received full repayment of the EUR 31.5 million loan for the Trento Proton Therapy Center in Italy.

Capital Markets Day

At the Capital Markets Day IBA will provide an update on its global proton therapy business, providing specific insights into the US market, latest developments in proton therapy innovation and the company's compact proton therapy system, Proteus[®]ONE*.

Olivier Legrain, Chief Executive Officer, will present an overview of IBA's proton therapy strategy, vision and financials focusing on the key trends in the industry. In addition, **Beth Klein**, VP US Sales will give an insight into IBA's commercial strategy in the region and **Frederic Genin**, IBA's Executive VP Product Development will provide an update on IBA's latest proton therapy innovation projects, including IBA's unique Pencil Beam Scanning technology and the first compact proton therapy gantry, which has been recently filed with the US FDA for approval. **Nicolas Deneff**, Product Manager, will also give an update on the growing wealth of clinical evidence to support the broadened use of proton therapy in the treatment of cancer. No new material information will be presented.

Presentations from the Capital Markets Day will be available to download from the Investor Relations section of the Company's website shortly after the session at <http://group.iba-worldwide.com/investor-relations>. A webcast of the event will not be available.

Krakow Proton Therapy Center

IBA has been selected by the Henryk Niewodniczanski Institute of Nuclear Physics of the Polish Academy of Sciences (IFJ) to the supply of the new extension of the IFJ Proton Therapy Center, Krakow, Poland. IBA has already been involved in the first two phases of construction of the proton therapy center. In this third phase IBA will provide a second Gantry Treatment Room equipped with



its cutting-edge Pencil Beam scanning technology. Financing of the project has been fully secured and final signature is expected by the end of the year.

Trento Proton Therapy Center

The Company also announces today the receipt of the payment from the ATreP (Agenzia Provinciale Per la Protonterapia) center in Trento, Italy, in repayment of a EUR 31.5 million loan facility signed in 2009. Trento features the world's most advanced proton therapy equipment, including the latest generation of IBA's Pencil Beam Scanning technology.

-ENDS-

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumour, sparing healthy surrounding tissue. Higher doses can be delivered to the tumour without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide utilize IBA solutions. This includes 16 proton therapy centres in operation and 10 centres under development. Over 25,000 patients have been treated on IBA equipment – more than all competitor installations combined.

About Proteus[®]ONE*

IBA Proteus[®]ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus[®]PLUS, developed with top clinical institutions worldwide. Proteus[®]ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy modality. Proteus[®]ONE is smaller, more affordable, easier to install, easier to operate and ultimately to finance. With Proteus[®]ONE, protons are possible for more patients worldwide.

**Proteus[®]ONE is the brand name of a new configuration of the Proteus[®] 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the

Press release |

Regulated information



development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For more information please contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 47 58 90

communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Mary-Jane Elliott, Amber Bielecka, Matthew Neal

+44 (0) 207 920 2354

IBA@consilium-comms.com